Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) EPS (Weighted Average and Diluted) (2019 - 2025)

10x Genomics (TXG) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.13 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 68.29% to -$0.13 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.35 through Dec 2025, up 77.12% year-over-year, with the annual reading at -$0.35 for FY2025, 76.97% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.13 in Q4 2025 for 10x Genomics, up from -$0.22 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.28 in Q2 2025 to a low of -$0.79 in Q3 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.3 across 5 years, with a median of -$0.31 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 470.0% in 2022 and later soared 187.5% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.17 in 2021, then increased by 11.76% to -$0.15 in 2022, then plummeted by 173.33% to -$0.41 in 2023, then increased by 0.0% to -$0.41 in 2024, then skyrocketed by 68.29% to -$0.13 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TXG at -$0.13 in Q4 2025, -$0.22 in Q3 2025, and $0.28 in Q2 2025.